Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM10AUP)

Drug Name

Biphenyl-3-ylcarbamic acid cyclohexyl ester Drug Info

Synonyms

565460-15-3; URB602; cyclohexyl biphenyl-3-ylcarbamate; Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate; URB-602; UNII-B8371SFA9K; CHEMBL77767; Monoacylglycerol Lipase Inhibitor, URB602; biphenyl-3-ylcarbamic acid cyclohexyl ester; B8371SFA9K; URB 602; N-Biphenyl-3-ylcarbamic acid, cyclohexyl ester; N-[1,1'-Biphenyl]-3-yl-carbamic Acid Cyclohexyl Ester; SCHEMBL4274165; Cyclohexylbiphenyl-3-ylcarbamate; CTK8C4433; DTXSID90450611; HHVUFQYJOSFTEH-UHFFFAOYSA-N; MolPort-003-850-812; EX-A1228; BCP19101; BDBM50128581; ANW-71925; ZINC13520725

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10979337
CAS Number: CAS 565460-15-3
TTD Drug ID: DM10AUP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[2]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[3]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[4]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[5]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[6]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[7]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[8]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[9]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[9]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
2	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3	The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6	The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
7	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
9	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.